Engineering Future Medicines

GEN-Y combines cutting-edge protein engineering, AI-based modelling and advanced automation to develop best-in-class antibodies for diagnostics and therapies

About Us

GEN-Y Biologics was formed in 2020 to license and productise superior antibody technologies derived from state-of-the-art technological platforms developed through their exclusive licensing partnership with National University of Singapore’s highly prestigious Life Sciences Institute

What We Do

Our technology employs a powerful method to screen human memory B cells from convalescent patients. Using a blend of bioinformatics, massive parallel sequencing and high throughput functional assays, we identify fully human monoclonal antibodies for research, therapy or diagnostics.

Delivering new solutions, improving
outcomes for patients


GEN-Y Biologics has an exciting pipeline of development opportunities in infectious illnesses and cancer.  The initial focus is on the dengue portfolio – representing a new paradigm in treatment of this infectious tropical disease.

Importantly, investors will benefit from the reassurance that GEN-Y Biologics is generating revenue from on-going ImTracker sales.

Latest News

A fast, sensitive and specific laboratory test for Immunity to covid-19 infection

GEN-Y’s ImTracker COVID Viral Variant Neutralization Test is a serological enzyme-linked immunosorbent assay (ELISA) that identifies neutralizing antibodies that are able to block infection by the latest viral variants that cause Covid. The ImTracker test has been granted the European Conformity CE Mark, and is available now as an In Vitro Diagnostic (IVD).

A wide range of RBD viral variants are available for sale  individually, including the latest Omicron sub-variants XBB and XBB.1.5.  See Order Products Section.

GEN-Y Biologics Dengue Treatment Featured on Channel News Asia

Kill the dengue virus in 6 hours instead of 2 weeks? Associate Professor Paul MacAry and his team from the Immunology Translational Research Programme at the National University of Singapore’s Yong Loo Lin School of Medicine (NUS Medicine) isolated a human antibody after screening “literally hundreds of millions” of antibodies derived from individuals who had recovered from dengue serotype 1. See the video of the interview with him.